InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split

InMed Pharmaceuticals Inc.

Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.
Board approved 1-for-20 reverse stock split on Oct 29, 2024; shares would reduce from ~14.36M to ~718k.
Reverse split requires no shareholder action; fractional shares not issued; trading symbol INM unchanged.
Company must evidence compliance by Dec 2; no assurance of regaining compliance by that date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.